The study by Douillard et al., showed the EGFR mutation status concordance between 652 matched tumor and base line plasma samples as 94.3 % and test sensitivity of 65.7 % and test specificity as 99.8 % [22]. The gene discussed is EGFR; the disease is neoplasm.